SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

zenagamtide

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If Phase 3 trials succeed, a regulatory filing would likely come no earlier than 2028-2029, with potential approval in the 2029-2030 timeframe. The drug is still investigational with no FDA submission filed.
Why 4/10
No hard dated binary catalyst is scheduled within the next ~12 months. The Phase 3 AMAZE trials began recruiting in August-September 2026 with estimated primary completion in 2028, so topline readouts are more than a year away. Zenagamtide is one of several pipeline assets at Novo Nordisk, a mega-cap company with many programs (CagriSema is more advanced, already filed for FDA approval).
Actionable Insight NEUTRAL

Watch for Phase 3 AMAZE trial enrollment updates and any interim analysis announcements from Novo Nordisk, though no topline readouts are expected before 2028. The more immediate pipeline catalyst for NVO is the FDA decision on CagriSema, which has already been filed. Zenagamtide remains a longer-term pipeline story with promising early data but no near-term binary event.

Price Chart

Loading chart...

Executive Summary

Zenagamtide (formerly amycretin, development code NN 9487) is Novo Nordisk's investigational unimolecular GLP-1/amylin receptor agonist for obesity and type 2 diabetes, being developed in both once-daily oral and once-weekly injectable formats. Phase 2 data showed up to 14.6% weight loss in type 2 diabetes and up to 24.3% in early obesity studies. The Phase 3 AMAZE program launched in mid-2026 and is actively recruiting, with estimated completion in 2028. The drug is not FDA approved and has no PDUFA date. For a mega-cap company like Novo Nordisk (NVO, ~$180B market cap) with multiple pipeline candidates, zenagamtide is a mid-to-long-term story with no near-term binary catalyst.

How It Works

Zenagamtide is a single engineered peptide molecule that simultaneously activates two appetite-regulating pathways: GLP-1 receptors (the same target as Ozempic/Wegovy) and amylin receptors (a satiety hormone pathway). It is designed to be taken either as a once-daily oral pill or a once-weekly subcutaneous injection for weight loss and type 2 diabetes.

Trial Status

Phase 2 data for type 2 diabetes was presented at ADA 2026 (June 2026) and published in The Lancet (August 2026), showing up to 14.6% mean weight loss and up to 1.71 percentage-point A1C reduction at 36 weeks. A Phase 1b/2a obesity study showed up to 24.3% mean weight loss at 36 weeks for the subcutaneous formulation. The Phase 3 AMAZE program launched in mid-2026: AMAZE 7 (injectable vs semaglutide, 650 patients, started Sep 2026) and AMAZE 9 (oral tablets vs placebo, 950 patients, started Aug 2026) are both recruiting. Additional AMAZE sub-studies cover sleep apnea and knee osteoarthritis. Primary completion dates for the Phase 3 trials are estimated in 2028.

The Two-Sided Case

▲ Bull Case4
Phase 2 data showed strong efficacy: up to 14.6% weight loss in type 2 diabetes and up to 24.3% in early obesity studies, competitive with or exceeding existing GLP-1 drugs.
The oral formulation could be a key differentiator in the obesity market, offering a pill alternative to injectables like Wegovy and Zepbound.
The unimolecular GLP-1/amylin mechanism is novel and could provide differentiated efficacy and tolerability vs Novo's own CagriSema (a combination of two separate molecules).
Multiple tracked institutional investors added or initiated positions in NVO in Q2 2026, including Goldman Sachs (add, +79%), Farallon Capital (doubled, +235%), and Fred Alger (new position worth $235M).
▼ Bear Case5
Phase 3 trials just started recruiting (Aug-Sep 2026) with estimated completion in 2028, meaning no near-term catalyst and years before potential commercialization.
Novo Nordisk's stock has fallen ~46% from its 52-week high of $64.16 to ~$40, reflecting broader pipeline and competitive concerns. Morgan Stanley downgraded NVO to Underweight in September 2026.
Intense competition: Eli Lilly's retatrutide (triple agonist) showed ~28.3% weight loss, and Novo's own CagriSema (already filed for FDA approval) may cannibalize zenagamtide's future market.
The drug is one of many pipeline assets at a mega-cap company; even positive data may have limited impact on NVO's share price relative to a small-cap biotech.
Several tracked institutional investors exited or severely trimmed NVO positions in Q2 2026, including Citadel (trim -50%), D.E. Shaw (trim -66%), and Jane Street (exit).

Upcoming Catalysts

  • Phase 3 AMAZE topline readouts (estimated 2028, no firm date set)
  • Potential interim analyses from Phase 3 trials (if any are scheduled, not yet disclosed)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 9

Hover a chip for the title
1 en.wikipedia.org2 prnewswire.com3 novonordisk-us.com4 midgardfinance.com5 remyresearch.com6 clinicaltrials.gov7 novonordisk-trials.com8 fool.com9 sciencehub.novonordisk.com